Orthocell (ASX:OCC) received regulatory clearance from the US Food and Drug Administration for its nerve repair product, Remplir, under the 510(k) pathway, allowing sales in the US market, according to a Friday filing with the Australian bourse.
Products delivered to the US will be manufactured at the company's Western Australia facility, the filing said.
Remplir is approved for sale in Australia, New Zealand, and Singapore, with pending approvals in Canada and Thailand in the next six months, according to the filing.
Shares were down 4% in morning trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.